Refine by
T Cell Receptor Articles & Analysis
56 news found
With an unwavering commitment to innovation and precision, CD Genomics continues to redefine the genomics research landscape. TCR-Seq, short for T Cell Receptor Sequencing, is an instrumental tool that enables scientists and researchers to decode the intricate tapestry of T cell populations within the immune ...
In the rapidly evolving field of drug delivery systems, novel therapies are continuously being developed to enhance the effectiveness and precision of treatment. CAR-T (chimeric antigen receptor T-cell) and CAR-NK (chimeric antigen receptor natural killer cell) therapies involve genetically ...
.: 793 SIRPα is an inhibitory receptor expressed mainly on myeloid cells and dendritic cells. Ligation of CD47 to SIRPα delivers a “don’t eat me” signal to suppress macrophage phagocytosis. ...
About CTH-001 CTH-001 is a Cartherics’ proprietary product candidate based on autologous (i.e., patient-derived) chimeric antigen receptor (CAR)-T cells targeting tumor associated glycoprotein 72 (TAG-72). Cartherics’ researchers identified that TAG-72 is present on the aberrant T cells associated ...
HPK1 kinase activity suppresses the immune functions of a wide range of cells including T cells and dendritic cells (DCs) 1. Therefore, inhibiting HPK1 activity serves as a promising approach for cancer immunotherapy. ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of ...
The capital raise enables Carina to complete its Investigational New Drug (IND) enabling studies and initiate a CAR-T clinical trial of our LGR5 CAR-T cell for patients with advanced colorectal (bowel) cancer. ...
Leading pharmaceutical research and development (R&D) teams can leverage MiXCR 4.0 for drug discovery pipelines, and for analyzing DNA sequencing data unraveling genomic information about antibodies, T-cell, and B-cell receptors. The initial stage of molecular identification during pre-clinical research remains a ...
(Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK viremia (BKV) in adult kidney transplant ...
ByKalaris
These two programs are currently being evaluated in Phase 2 studies, targeting a variety of late-stage, difficult-to-treat cancer types, including breast cancer for praluzatamab ravtansine, and squamous non-small cell lung cancer, and head and neck squamous cell carcinoma for CX-2029. CytomX’s clinical pipeline also includes cancer immunotherapeutic ...
CX-904 is a conditionally activated T-cell-engaging bispecific (TCB) designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment. ...
” VEL-101 is a pegylated monoclonal antibody fragment that binds to and blocks CD28-mediated effector-T cell co-stimulation, without blocking CTLA-4, an important protein receptor found on T cells that acts as a natural brake on the body’s immune responses. VEL-101 is, therefore, expected to have a ...
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually at the ...
Date and Time: May 18, 2022, 5:30 p.m. to 6:30 p.m. ET Title: Armoring T-cells with regulatable, membrane tethered cytokines using improved drug-responsive domain technology (cytoDRiVE®) Presenter: Dr. ...
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the fiscal quarter ...
These two programs are currently being evaluated in Phase 2 studies, targeting a variety of late-stage, difficult-to-treat cancer types, including breast cancer for praluzatamab ravtansine, and squamous non-small cell lung cancer, and head and neck squamous cell carcinoma for CX-2029. CytomX’s clinical pipeline also includes cancer immunotherapeutic ...
The data demonstrate that CB-011 CAR-T cells are cytotoxic against BCMA-expressing tumor cells and are resistant to killing by both allogeneic T cells and natural killer (NK) cells. ...
The Company currently has a pipeline of five anti-glycan mAbs: SC129, SC134, SC88 and SC27 that target solid tumours including pancreatic, small cell lung, colorectal and gastric, and SC2811 that targets a glycolipid on T cell stem cells. ...
ByScancell
(Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched ...
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced its financial results for the fiscal year 2021 ended December 31, 2021 and provided a ...